Apollo Hospitals Enterprise Ltd: Valuation Shift Signals Fair Price Amid Robust Returns

Valuation Metrics Reflect Changing Market Sentiment

Apollo Hospitals currently trades at a price-to-earnings (P/E) ratio of 65.40, a level that has prompted a downgrade in its valuation grade from attractive to fair as of 11 May 2026. This P/E multiple, while high, remains below some peers such as Max Healthcare, which is classified as very expensive with a P/E of 75.7. The price-to-book value (P/BV) stands at 13.49, signalling a premium valuation relative to the company’s net asset base.

Other valuation multiples further illustrate the premium at which Apollo Hospitals is priced. The enterprise value to EBITDA (EV/EBITDA) ratio is 35.63, and the enterprise value to EBIT (EV/EBIT) ratio is 46.42, both indicating elevated expectations for earnings growth and operational efficiency. The PEG ratio of 1.85 suggests that while the stock is expensive on earnings, growth prospects somewhat justify the premium, though it remains below the peer Max Healthcare’s PEG of 2.47.

Strong Operational Metrics Support Valuation

Despite the high multiples, Apollo Hospitals demonstrates solid operational performance. The return on capital employed (ROCE) is a healthy 18.27%, while the return on equity (ROE) stands at 20.63%, reflecting efficient capital utilisation and profitability. Dividend yield remains modest at 0.22%, consistent with the company’s growth-oriented capital allocation strategy.

These metrics underpin the company’s mojo score of 75.0, which has been upgraded from a previous hold to a buy rating, signalling improved confidence in the stock’s medium-term prospects. The market capitalisation classification as a large-cap stock further emphasises its established position within the hospital sector.

Price Performance Outpaces Broader Market

Apollo Hospitals’ share price has shown commendable strength, closing at ₹8,897.35 on 6 July 2026, up 2.30% on the day and touching a 52-week high of ₹8,917.95. The stock’s 52-week low was ₹6,680.00, indicating significant appreciation over the past year.

When compared to the Sensex, Apollo Hospitals has delivered superior returns across multiple time horizons. Year-to-date (YTD), the stock has surged 26.34%, while the Sensex has declined by 8.75%. Over one year, Apollo Hospitals gained 17.78% against the Sensex’s negative 6.58%. Longer-term returns are even more impressive, with a three-year return of 75.50% versus the Sensex’s 19.26%, a five-year return of 138.31% compared to 48.16%, and a remarkable ten-year return of 568.87% against the Sensex’s 186.48%.

Contextualising Valuation Within the Hospital Sector

Within the hospital sector, Apollo Hospitals’ valuation multiples are elevated but comparatively reasonable. Max Healthcare, a key peer, trades at a significantly higher P/E of 75.7 and an EV/EBITDA of 51.27, reflecting a more stretched valuation. This relative positioning suggests that while Apollo’s shares are not cheap, they offer a more balanced risk-reward profile within the sector.

The company’s EV to capital employed ratio of 8.48 and EV to sales ratio of 5.32 further indicate that investors are willing to pay a premium for its operational scale, brand strength, and growth prospects. These multiples, combined with the company’s robust ROCE and ROE, support the fair valuation grade assigned recently.

Investment Implications and Outlook

Investors should note that the shift from an attractive to a fair valuation grade signals a more cautious stance on price appreciation potential in the near term. The high P/E and P/BV ratios imply that much of the company’s growth expectations are already priced in. However, Apollo Hospitals’ consistent earnings growth, strong return ratios, and sector leadership provide a solid foundation for sustained performance.

Given the stock’s outperformance relative to the broader market and peers, it remains a compelling option for investors seeking exposure to the healthcare sector’s growth story. The upgrade in mojo grade to buy reflects improved confidence in the company’s fundamentals and valuation balance.

Conclusion: Balancing Valuation with Growth Potential

Apollo Hospitals Enterprise Ltd’s recent valuation adjustment to a fair grade reflects the market’s recognition of its premium pricing amid strong fundamentals. While the elevated P/E and P/BV ratios suggest limited upside from current levels, the company’s robust returns, operational efficiency, and sector leadership justify continued investor interest.

For investors prioritising quality and growth within the hospital sector, Apollo Hospitals remains a strong buy candidate, supported by a mojo score of 75.0 and a large-cap status. The stock’s consistent outperformance relative to the Sensex and peers underscores its resilience and growth trajectory, making it a key holding for long-term portfolios.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today